Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
333 studies found for:    Open Studies | "Triplets"

Modify this search | How to Use Search Results

Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Triplets" (333 records)
Need help? See Downloading Content for Analysis
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Not yet recruiting A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Neoplasms;   Triple-Negative Breast Neoplasm;   Triple-Negative Breast Cancer;   Triple Negative Breast Cancer;   ER-Negative PR-Negative HER2-Negative Breast Neoplasms;   ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions: Biological: Bavituximab;   Drug: Taxane
2 Recruiting Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple-Negative Breast Cancer;   Triple Negative Breast Neoplasms
Intervention: Biological: Personalized polyepitope DNA vaccine
3 Recruiting Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple Negative Breast Neoplasms;   Triple-Negative Breast Cancer
Interventions: Biological: Personalized synthetic long peptide vaccine (Poly ICLC);   Drug: Poly ICLC
4 Recruiting Cisplatin vs Paclitaxel for Triple Neg
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
5 Recruiting Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Other: Chemotherapy
6 Unknown † Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
Condition: Triple Negative Breast Cancer
Interventions: Procedure: Needle core biopsies;   Procedure: Needle core biopsies of metastatic lesion
7 Not yet recruiting Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Condition: Triple-negative Breast Cancer
Interventions: Drug: IMMU-132 infusion is administered to participants in one arm for the study;   Drug: IMMU-132 plus Carboplatin infusion
8 Unknown † Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Paclitaxel plus carboplatin;   Drug: Paclitaxel and epirubicin
9 Recruiting Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Condition: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.
Interventions: Drug: CDX-011;   Drug: Capecitabine
10 Recruiting Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
Conditions: Breast Cancer;   Capecitabine;   Triple Negative Breast Cancer
Intervention:
11 Unknown † Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Paclitaxel Cisplatin
12 Recruiting Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173)
Condition: Triple Negative Breast Neoplasms
Interventions: Biological: Pembrolizumab;   Drug: Nab-paclitaxel;   Drug: Anthracycline (doxorubicin);   Drug: Cyclophosphamide;   Drug: Carboplatin
13 Unknown † Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients
Condition: Triple Negative Local Advanced Breast Cancer
Intervention: Drug: docetaxel oxaliplatin
14 Recruiting Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Condition: Metastatic Triple Negative Breast Cancer
Intervention: Drug: Combination of Veliparib + Lapatinib
15 Recruiting Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm
Condition: Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm
Intervention: Procedure: Blood samples of 10 mL
16 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
17 Recruiting Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Condition: Triple Negative Breast Neoplasms
Interventions: Drug: Docetaxel;   Drug: Carboplatin
18 Recruiting Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Conditions: Breast Cancer;   Early Stage;   Triple Negative Breast Cancer
Interventions: Drug: Enzalutamide;   Behavioral: assessment
19 Not yet recruiting Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Pembrolizumab;   Drug: Cyclophosphamide
20 Recruiting Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Condition: Triple-negative Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years